Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX 4291 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX 4291 (Part A) | EXPERIMENTAL | Participants will be administered single ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part B) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part C) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered single or multiple ascending doses of placebo. |
| Name | Type | Description |
|---|---|---|
| MBX 4291 | DRUG | MBX 4291 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo: Placebo will be administered subcutaneously (SC) |
Inclusion Criteria: * Age of \>18 to ≤65 years at the time of signing the informed consent. * Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline. * Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline. Exclusi...
Top 20 of 35 competitors
MBX 4291 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development, with an ongoing study evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in adult participants with obesity.
MBX 4291 targets the GLP-1/GIP receptors. GLP-1 and GIP are incretin hormones involved in glucose metabolism and appetite regulation, making them relevant targets for obesity treatment. The drug is designed to modulate these pathways, though its exact mechanism is still under investigation.
MBX 4291 is being developed by MBX Biosciences, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol MBX. The company is conducting clinical trials to evaluate the drug's potential as a treatment for obesity.
MBX 4291 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and pharmacological properties in humans.
MBX 4291 is being studied in a Phase 1 clinical trial registered as NCT07142707. This randomized, double-blind, placebo-controlled study is recruiting 124 adult participants with obesity in the United States. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MBX 4291.